94 related articles for article (PubMed ID: 23319808)
1. Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis.
Martini M; Russo M; Lamba S; Vitiello E; Crowley EH; Sassi F; Romanelli D; Frattini M; Marchetti A; Bardelli A
Cancer Res; 2013 Mar; 73(6):1912-21. PubMed ID: 23319808
[TBL] [Abstract][Full Text] [Related]
2. Clinical Evidence on the Interaction Between MLK4, KRAS and Microsatellite Instability to Determine the Prognosis of Early-Stage Colorectal Carcinoma.
Brandl L; Horst D; Grünewald TGP; Mayerle J; Sendelhofert A; Neumann J; Kirchner T; De Toni EN
Cell Physiol Biochem; 2019; 53(5):820-831. PubMed ID: 31701729
[TBL] [Abstract][Full Text] [Related]
3. Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
Marusiak AA; Stephenson NL; Baik H; Trotter EW; Li Y; Blyth K; Mason S; Chapman P; Puto LA; Read JA; Brassington C; Pollard HK; Phillips C; Green I; Overman R; Collier M; Testoni E; Miller CJ; Hunter T; Sansom OJ; Brognard J
Cancer Res; 2016 Feb; 76(3):724-35. PubMed ID: 26637668
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.
Lemieux E; Cagnol S; Beaudry K; Carrier J; Rivard N
Oncogene; 2015 Sep; 34(38):4914-27. PubMed ID: 25500543
[TBL] [Abstract][Full Text] [Related]
5. Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner.
Kim SH; Ezhilarasan R; Phillips E; Gallego-Perez D; Sparks A; Taylor D; Ladner K; Furuta T; Sabit H; Chhipa R; Cho JH; Mohyeldin A; Beck S; Kurozumi K; Kuroiwa T; Iwata R; Asai A; Kim J; Sulman EP; Cheng SY; Lee LJ; Nakada M; Guttridge D; DasGupta B; Goidts V; Bhat KP; Nakano I
Cancer Cell; 2016 Feb; 29(2):201-13. PubMed ID: 26859459
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells.
Marusiak AA; Prelowska MK; Mehlich D; Lazniewski M; Kaminska K; Gorczynski A; Korwat A; Sokolowska O; Kedzierska H; Golab J; Biernat W; Plewczynski D; Brognard J; Nowis D
Oncogene; 2019 Apr; 38(15):2860-2875. PubMed ID: 30552384
[TBL] [Abstract][Full Text] [Related]
7. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
Song Q; Sun X; Guo H; Yu Q
Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
[TBL] [Abstract][Full Text] [Related]
8. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
9. Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.
Holck S; Bonde J; Pedersen H; Petersen AA; Chaube A; Nielsen HJ; Larsson LI
Hum Pathol; 2016 Aug; 54():37-46. PubMed ID: 27036313
[TBL] [Abstract][Full Text] [Related]
10. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
11. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
12. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
13. Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K).
Eder S; Arndt A; Lamkowski A; Daskalaki W; Rump A; Priller M; Genze F; Wardelmann E; Port M; Steinestel K
Cancer Lett; 2017 Jan; 385():160-167. PubMed ID: 27793696
[TBL] [Abstract][Full Text] [Related]
14. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
[TBL] [Abstract][Full Text] [Related]
15. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition.
Cagnol S; Rivard N
Oncogene; 2013 Jan; 32(5):564-76. PubMed ID: 22430215
[TBL] [Abstract][Full Text] [Related]
17. Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation.
Duhamel S; Hébert J; Gaboury L; Bouchard A; Simon R; Sauter G; Basik M; Meloche S
Cancer Res; 2012 Feb; 72(3):626-35. PubMed ID: 22298595
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
19. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
[TBL] [Abstract][Full Text] [Related]
20. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.
Morkel M; Riemer P; Bläker H; Sers C
Oncotarget; 2015 Aug; 6(25):20785-800. PubMed ID: 26299805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
